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Abstract
Bipolar disorder is a debilitating mental illness characterized by recurrent episodes of
mania and depression. FDA-approved drugs lithium and valproate, are the most common
treatments for this disorder. Currently, omega-3 fatty acids are being researched as an
alternative treatment, free of the negative side effects valproate and lithium exhibit. The
mechanisms by which valproate and lithium work are unclear, however they effectively lower
intracellular inositol levels. Valproate and omega-3 fatty acids similarly inhibit yeast cell
growth as well as protein kinase C activity. We hypothesize that omega-3 fatty acids can also
decrease inositol levels. A prodrug combining structural properties of valproate and omega-3
fatty acids was synthesized and tested on the growth of Saccharomyces cerevisiae yeast cells.
Results suggest the mechanisms by which valproate and omega-3 fatty acids lower inositol
levels are similar.
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Introduction
Bipolar disorder is a chronic mental illness affecting approximately 1.3-1.5% of the
American population (Azab et al., 2007; Azab and Miriam L. Greenberg, 2006). The disorder
is characterized by mood swings ranging from lows of depression to highs of mania. Lithium
and valproate are two of the most commonly used drugs for treating the symptoms of
bipolar disorder. Although the mechanisms by which they remedy bipolar disorder are not
clearly known, studies have shown both valproate and lithium target the inositol biosynthetic
pathway, inhibiting steps of inositol synthesis, and effectively lowering inositol levels (Vaden
et al., 2001). Inositol a is a chemical compound that forms the basis of many second
messenger systems in cells of the human body. As a second messenger molecule, inositol
relays signals from the surface of the cell to the targets within that cause changes in cell
activity. Inositol is also an essential component of cell membranes.
Lithium and valproate are not always effective in treating bipolar disorder, thus there
is a need for more effective treatments. Currently omega-3 fatty acids are being researched as
an alternative treatment for bipolar disorder. In combination with other treatments, omega-3
fatty acids effectively reduce symptoms of this illness without the adverse side effects
exhibited by lithium and valproate (Ross et al., 2007). Interestingly valproate (Murray and
Greenberg, 2000) and omega-3 fatty acids similarly inhibit growth in yeast cells (Murray,
unpublished) and also the activity of protein kinase C (PKC) (Mirnikjoo et al., 2001), an
enzyme involved in the inositol biosynthetic pathway. Therefore we hypothesize both
compounds suppress inositol levels in yeast by similar mechanisms of action. My first goal in
this research project is to synthesize a chloro linoleate acylal (α-chloropropyl linoleate) in a
one-pot reaction involving linoleic acid, a model system for omega fatty acids. Finally, I
would like to determine the effects of the prodrug on the inositol biosynthetic pathway by
3

measuring the growth of wild type (SMY7) and mutant (SH1 and SH7) Saccaromyces cerevisiae
yeast in the presence and absence of the synthesized compound. Saccaromyces cerevisiae yeast
serves as a model system for the inositol biosynthetic pathway in the human body and its cell
growth is dependent on inositol levels. SMY7 yeast produce normal levels of inositol
whereas SH1 yeast under produce inositol and SH7 yeast over produce inositol. The prodrug
has structural properties of both valproate and omega-3 fatty acids. Understanding how it
affects the inositol biosynthetic pathway will shed light on the mechanisms by which both
compounds work and contribute to evidence for the possible use of omega-3 fatty acids in
treatment of bipolar disorder.

Methodology
PRODRUG SYNTHESIS:
Trial 1
A 50 ml round bottom flask and spin vane were dried in the oven overnight. The
subsequent day the flask was placed in an ice bath over a magnetic stir plate, and capped
with a calcium chloride drying tube. Cyclohexane, linoleic acid and thionyl chloride were
added to the flask and the calcium chloride drying tube replaced with a water-cooled
condenser. The mixture was refluxed 30 minutes to create linoleyl chloride. Reflux involves
boiling the solution with minimal evaporation and continual cooling of the vapor which is
returned to the flask as a liquid. The linoleyl chloride was allowed to cool to room
temperature after which the condenser was replaced with the drying tube. Propanal and zinc
oxide (catalyst) were added to the flask and stirred at room temperature for 90 minutes. The
solution was extracted three times using fresh dichloromethane and deionized water each
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time. The solution was dried with anhydrous sodium sulfate for three days, rotovapped for
20 minutes, and placed on a vacuum line for 24 hours to ensure the removal of solvent from
the desired product. The density and actual yield of the product was determined. 1H and 13C
nuclear magnetic resonance (NMR) and infrared (IR) spectroscopy were performed to
analyze the product in relation to the starting materials, propanal and linoleic acid. Table 1
summarizes the amount of each compound used this trial.

Table 1

Compound

Moles

Grams

Volume
(mL)

Density
(g/mL)

Molecular weight
(g/mol)

Cyclohexane

_

_

10

0.779

84.16

linoleic acid

0.0064

_

2

0.9

280.45

thionyl chloride

0.0084

_

0.62

1.64

118.97

Propanal

0.0064

_

0.46

0.81

58.08

zinc oxide

0.00128

0.104

_

5.61

81.41

_

_

60

_

_

dichloromethane

Trial 2
A 100ml round bottom flask was dried in the oven overnight. The flask was placed
on an ice bath over a magnetic plate and capped with a calcium chloride drying tube.
Cyclohexane, linoleic acid, thionyl chloride and a spin vane were added to the flask. The
drying tube was replaced with a water condenser and the mixture refluxed for 45 minutes at
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80˚C. The linoleyl chloride was allowed to cool to room temperature. The water condenser
was again replaced by the drying tube. Propanal and zinc oxide (catalyst) were added to the
flask and stirred at room temperature for 120 minutes. The mixture was extracted three
times using fresh dichloromethane and deionized water, then dried with anhydrous sodium
sulfate to remove excess water. After a few minutes of drying, the solution was rotovapped.
In the midst of the rotary evaporation the flask containing the solution broke in the
apparatus. The solution was collected as best as possible, reextracted, dried with anhydrous
sodium sulfate and rotovapped for 10-20 minutes. 1H and 13C NMR of the product were
performed. The product was placed on a vacuum line for futher purification and 1H and 13C
NMR were performed again for analysis of the product in relation to the starting materials
(propanal and linoleic acid). Table 2 summarizes the amount of each compound used in this
trial.

Table 2

Compound

Moles

Grams

Volume
(mL)

Density
(g/mL)

Molecular weight
(g/mol)

Cyclohexane

_

_

20

0.779

84.16

linoleic acid

0.0128

_

4

0.9

280.45

thionyl chloride

0.0168

_

1.24

1.64

118.97

Propanal

0.0128

_

0.92

0.81

58.08

zinc oxide

0.0026

0.208

5.61

81.41

_

_

_

_

dichloromethane

40
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BIOLOGICAL TESTING:
Trial 1
Liquid media for the yeast was prepared using the ingredients listed in Table 3. Two
types of media were made: one with inositol (I+) and one without inositol (I-). The
ingredients for 500 mL of media were mixed into two 1 L Erlenmeyer flasks, labeled either
I+ or I- . Media in the I+ labeled flask included myo-inositol whereas the flask labeled I- did
not. These flasks were covered with aluminum foil and autoclaved for 25 minutes along with
three empty 250 mL Erlenmeyer flasks, two labeled I- and one labeled I+. Then, 100 mL
each of the I+ and I- media was poured into its corresponding 250 mL flask. The I+ flasks
was then inoculated with plated SH1 yeast and labeled as such. One of the I- flasks was
inoculated with plated SMY7 yeast and the other with plated SH7 yeast and labeled
respectively. The inoculations were allowed to grow for 24-30 hours in a shaker bath (150
rpm; 30 °C). After this, 1000 µl of stock I+ media was pipetted into a cuvette as a control,
900 µl of stock I+ media was placed in a second cuvette as well as 100 µl from the I+. 1000
µl of stock I- media was pipetted into a cuvette as a control, and for each I- flask 900 µl of
stock I+ media was placed in a cuvette as well as 100 µl from the overnight flask.
Concentration readings were then taken with the spectrophotometer to confirm that there
was enough growth to continue on with next step (at least 0.1).
After autoclaving six new empty 250 mL Erlenmeyer flasks, each flask was labeled
wildtype, underproducer, overproducer, wildtype + PD, underproducer + PD, and
overproducer + PD (PD corresponds to prodrug). 100 mL of I+ media was added to the
underproducer and underproducer + PD flasks and 100 mL of I- media was added to each
of the other four flasks. Based on calculations using the formula C1V1 = C2V2, specific
volumes of the I+ and I- overnight solutions were added to the corresponding flasks
7

containing new media. The prodrug flasks contained both the overnight solution and a
prodrug concentration of 5.0 mM. These six flasks were placed in a shaker bath (150 rpm; 30
°C) for 24-30 hours. Another concentration reading was taken of the resulting cells using the
spectrophotometer. A 10-3 dilution was then performed on the resulting solutions For each
solution 10 µl of the solution and 990 µl of water were placed in a 1 mL microcentrofuge
tube. Each was spread on a previously made YPD plate and labeled (see Table 3). The plates
were incubated for 48 hours and then the resulting yeast colonies were counted.

Trial 2
The same steps for preparing the yeast and allotting the prodrug in Trial 1 were repeated. A
10-3 dilution was performed on the resulting solutions and plated on YPD plates. The plates
were labels and incubated for 48 hours and the resulting yeast colonies counted.

Table 3
Ingredient
Vitamin Free Yeast Base
Ammonium sulfate
Glucose
100x vitamins
Myo-inositol*
Adenine
Arginine
Histidine
Leucine
Lysine
Methionine
Threonine
Tryptophan
Uracil
Deionized H2O
Agar**
*Only used for I+ media for SH1/underproducer yeast
**Only used to make YPD plates
8

Amount/L
0.345 mL
1.005 mL
10 g
10 g
5 mL
7.5 mL
1 mL
1 mL
2 mL
1 mL
1 mL
8 mL
1 mL
8 mL
500 mL
10g

Results
NMR and IR ANALYIS:
Trial 1 yielded a product with a density of .966g/ml and actual yield of 1.9ml. Table 4
summarizes the important spectral features in the IR, 1H NMR, and 13C NMR spectroscopy
for propanal, linoleic acid and the product, α-chloropropyl linoleate. The important spectral
features for Trial 1 and Trial 2 were the same.

Table 4
Important Spectral Features
Compound

IR (cm-1)
C=O (1734)

1

H NMR (ppm)
aldehyde H @ 9.8

13

C NMR (ppm)
aldehyde carbon @ 204

C=O (1707)

diene H’s @ 5.4

acid carbon @ 180

C=O (1761)

acylal H, triplet @ 6.4

Present:

C-O (1136)

present

acylal carbon @ 85

aldehyde H @ 9.8

ester carbon @ 172

is gone

Absent:

Propanal

Linoleic acid

O-H (2927,
broad)

α-chloropropyl
linoleate (product)

aldehyde carbon @ 204
acid carbon @ 180
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BIOLOGICAL TESTING:
Trial 1

Graph 1: The results of colony growth in Trial 1.
Prodrug

CELL TYPE

SH2 (overproducer)

No prodrug

0
0
1010

SH1 (underproducer)

SMY7 (wildtype)

1430
0
1385
NUMBER OF COLONIES

Trial 2

Graph 2: The results of colony growth in Trial 2.
Prodrug

CELL TYPE

SH2 (overproducer)

SH1 (underproducer)

SMY7 (wildtype)

No prodrug

0
1300
0
750
14
175
NUMBER OF COLONIES
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Discussion
PRODRUG SYNTHESIS:
The IR of the prodrug showed two main diagnostic peaks that indicate the success
of the reaction. There was a peak at 1761 cm-1 and at 1136 cm-1, which are characteristic of
C=O and C-O groups respectively. The 1H NMR propanal 9.8 ppm that was absent for the
prodrug. Also the characteristic acylal proton showed up as a triplet peak at 6.4ppm for the
prodrug. The 13C NMR confirmed the success of the reaction. Most of the carbon atoms in
the propanal and linoleic acid stayed in relatively the same positions throughout the reaction.
The peak for the aldehyde carbon in propanal (204ppm) as well as the peak for the acid
carbon in linoleic acid (180 ppm) were absent in the13C NMR of the prodrug. Instead a peak
for the acylal carbon at 85 ppm and for the ester carbon at 172 ppm were present for the
prodrug, indicating we had obtained the desired product.

BIOLOGICAL TESTING:
We hypothesized that the prodrug would effectively lower the inositol levels of the
yeast causing a decrease in cell growth. In Trial 1 wildtype (SMY7) yeast treated with the
prodrug had no growth. The yeast underproducing inositol (SM1) had a less drastic decrease
in growth. Yeast overproducing inositol did not grow with or without the drug, so there may
have been a mistake made in plating the cells. In Trial 2 the wildtype yeast treated with
prodrug had low cell counts (14) in comparison to the control (175). Both the
underproduing and overproducing yeast treated with prodrug had no growth.

11

Conclusion
Based on the NMR and IR analysis, the prodrug synthesis was successful for both
trials, inspite of the accident that could have resulted in contamination for Trial 2. Overall
the prodrug is effective at inhibiting growth however the inhibition of growth was the same
in all three strains. This suggests the effect of the prodrug is not related to the inositol
biosynthetic pathway. However a comparison of cell counts for each yeast cell type in Trial 1
and Trial 2 does not demonstrate similar numbers. Further testing needs to be done for
results from the biological testing to be concrete. Future experiments should include more
trials and various prodrug concentrations in order to obtain a broader range of data.
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